PAIN

Vector invests in Whoopi Wellness to co-develop peptide-based women's wellness products.

Vector invests in Scoreboard to co-develop peptide products with NBA Hall of Famer Gary Payton.

Vector grants 150,000 stock options at C$1.80 to an officer, pending TSXV approval.

Vector Science signs a standard IR deal with RedChip, pending TSXV approval.

Only the first suite's 55,000 vials are real; all major growth is projection.

Vector filed a US provisional patent but disclosed no clinical or financial progress.

Vector secures a decade-long U.S. manufacturing deal, but offers no financial details.

Big promises, little evidence—investors should wait for real numbers before acting.

Patent filing, not product proof—big promises, but no data or revenue yet.

Celebrity hires alone don’t prove business traction or near-term investor upside.

Big-name hire, but no proof the product works or will sell anytime soon.

This is a routine director stock option grant with no immediate investment signal.

This is a high-risk, early-stage bet with long timelines and little near-term visibility.

Big promises, but real results are years away and far from guaranteed.

Board appointments alone don’t prove commercial progress—wait for real milestones before acting.

Patent filing is all talk—no data, no funding, no near-term investor payoff.

This is a shell listing with hype, not a proven business or near-term revenue story.